Sreejith Parameswaran
@sreejithdr.bsky.social
920 followers 330 following 59 posts
Nephrologist, Learner, Teacher. I’m my own competition on the path to better!
Posts Media Videos Starter Packs
Gandhi Jayanthi Morning 12K 🏃🏽‍♂️
With humidity above 80%, I was drenched in sweat as if I took a shower during the run! 🥵
CKDu as a Tubulointerstitial Disease - a narrative review I wrote with Dr Magdalena Maduro :
kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F...
Thank You @pranavgarimella for asking us to contribute for @akdhjournal
Agree with you on the political angle - if someone moved to BlueSky to stay away from all the political drama, they were fooled. Only difference is that it is one sided on BlueSky.
I wish people kept both accounts & discussed science & Nephrology in BlueSky & politics in Twitter!
Sunday Morning 12K 🏃🏽‍♂️
The biggest threat to the 'streak' are the medical conferences happening almost every weekend! 😅
If this is not a calamity, what is?
172,000 people died in 2023 on Indian roads, translating into 1317 accidents & 474 deaths every day or 55 accidents and 20 deaths every hour!! 🫢
Most of them in young & productive age.
This is worse than dropping a nuclear bomb!
#RoadSafety
Turns out we ourselves (how we like, share) are to blame for SoMe toxicity and not algorithms! 😐
www.newscientist.com/article/2492...
Sunday Morning 12K 🏃🏽‍♂️
Sunday Morning 12K 🏃🏽‍♂️
(showing 13K because of tracking error).
#MakingProgress
That is a wrap!
Thank you for staying with me on this thread!
#AKI #CCNA 2.0
18/18
While biomarkers have the potential to enhance our ability to care for people with AKI, we need more work in this area.
Even when we have useful biomarkers, they are expected to refine our abilities and not to replace Creatinine & U.O.
#AKI #CCNA 2.0
17/18
What is the future of AKI Biomarkers?
#AKI #CCNA 2.0
16/18
A novel point-of-care (POC) uNGAL Dipstick was developed at the Columbia University by Dr Jonathan Barasch and was tested @JipmerNephro for predicting AKI risk in patients seeking treatment at the emergency services
pubmed.ncbi.nlm.nih.gov/40630276/
#AKI #CCNA 2.0
15/18
Despite all these, there are many challenges & limitations when it comes to applying AKI biomarkers in routine clinical practice
pubmed.ncbi.nlm.nih.gov/33021646/
#AKI #CCNA 2.0
14/18
The proposed new diagnosis and staging system for AKI incorporating Biomarkers
pubmed.ncbi.nlm.nih.gov/33021646/
#AKI #CCNA 2.0
12/18
03 - Diagnosis, Aetiology & Management
#AKI #CCNA 2.0
11/18
The NephroCheck(R) Test is validated & FDA approved
#AKI #CCNA 2.0
10/18
Let us see what their current clinical applications are.
Please refer to the ADQI consensus statement too: pubmed.ncbi.nlm.nih.gov/33021646/
01 - AKI Risk Assessment
#AKI #CCNA 2.0
7/18
AKI Biomarkers can be categorised broadly into three categories:
1️⃣Function Markers
2️⃣Stress Markers
3️⃣Damage Markers
#AKI #CCNA 2.0
6/18
It is not that there are no biomarkers to assess kidney injury & damage. Many were studied extensively and newer ones are being identified
#AKI #CCNA 2.0
5/18
Urine output is also not exactly reliable as a marker of kidney function.
#AKI #CCNA 2.0
4/18
The limitations of Serum Creatinine as a marker of kidney function are well known.
#AKI #CCNA 2.0
3/18
Biomarkers are everywhere in clinical medicine & are well entrenched in Cardiology, Oncology, etc. However, in Nephrology, Bioamarkers are still not 'mainstream'.
#AKI #CCNA 2.0
2/18